| Schedule of Basic and Diluted Earnings Per Share |
Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except per share data) |
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Numerator |
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in net assets resulting from operations |
|
$ |
94,775 |
|
|
$ |
(10,318 |
) |
|
$ |
189,339 |
|
|
$ |
(13,654 |
) |
Less: Total distributions declared |
|
|
(67,379 |
) |
|
|
(59,993 |
) |
|
|
(132,153 |
) |
|
|
(117,875 |
) |
Total Earnings (loss), net of total distributions |
|
|
27,396 |
|
|
|
(70,311 |
) |
|
|
57,186 |
|
|
|
(131,529 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss), net of distributions attributable to common shares |
|
|
27,108 |
|
|
|
(70,311 |
) |
|
|
56,552 |
|
|
|
(131,529 |
) |
Add: Distributions declared attributable to common shares |
|
|
66,672 |
|
|
|
59,431 |
|
|
|
130,696 |
|
|
|
116,693 |
|
Numerator for basic and diluted change in net assets per common share |
|
$ |
93,780 |
|
|
$ |
(10,880 |
) |
|
$ |
187,248 |
|
|
$ |
(14,836 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator |
|
|
|
|
|
|
|
|
|
|
|
|
Basic weighted average common shares outstanding |
|
|
141,390 |
|
|
|
124,255 |
|
|
|
138,338 |
|
|
|
121,292 |
|
Common shares issuable |
|
|
694 |
|
|
|
— |
|
|
|
1,249 |
|
|
|
— |
|
Weighted average common shares outstanding assuming dilution |
|
|
142,084 |
|
|
|
124,255 |
|
|
|
139,587 |
|
|
|
121,292 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in net assets per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.66 |
|
|
$ |
(0.09 |
) |
|
$ |
1.35 |
|
|
$ |
(0.12 |
) |
Diluted |
|
$ |
0.66 |
|
|
$ |
(0.09 |
) |
|
$ |
1.34 |
|
|
$ |
(0.12 |
) |
|
| Schedule of Number of Anti-diluted Shares As Calculated Based on Weighted Average Closing Price of Common Stock |
The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and six months ended June 30, 2023, and 2022, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
Anti-dilutive Securities |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Unvested common stock options |
|
|
3,146 |
|
|
|
16 |
|
|
|
2,499 |
|
|
|
24 |
|
Restricted stock units |
|
|
9,555 |
|
|
|
2 |
|
|
|
8,714 |
|
|
|
17 |
|
Unvested restricted stock awards |
|
|
65,346 |
|
|
|
— |
|
|
|
59,854 |
|
|
|
— |
|
Performance awards* |
|
|
— |
|
|
|
1,685 |
|
|
|
— |
|
|
|
1,116 |
|
*Included in these amounts are shares related to certain equity-based awards, which fully vested in May 2022 and delivered in May 2023 and thus no longer outstanding for purposes of calculating earnings per share.
|